Economy
Financial Markets
Commodities
Industries
Energy
Real Estate
Local listed Company
Overseas-listed Company
Foreign Company
Industrial Parks


 
Company - Overseas
 Search News  Or
Nasdaq-listed China Biologic sees profit for Q1 over double

May. 9, 2012 (China Knowledge) - China Biologic Products Inc<CBPO>, one of the leading plasma-based biopharmaceutical companies in the county, has posted US$13 million-net profit attributable to shareholders for the first quarter of 2012, reflecting a year-on-year jump of 105.4% from US$6.3 million.

On a non-GAAP basis, the Nasdaq-listed firm's net profit attributable to shareholders surged 59.6% year on year from US$8 million to US$12.7 million in the reporting period.

Diluted earnings per American Depositary Share were US$0.44 in the three months ended Mar. 31, 2012, more than US$0.23 in the first quarter of 2011. Non-GAAP diluted earnings per ADS reached US$0.48 in the first quarter of this year, compared with US$0.31 in the same period of last year.

Total sales increased 37% from a year earlier to US$47.2 million in the first quarter of 2012.

Gross profit increased 25.2% year on year to US$31.5 million in the same period, with gross margin of 66.7%, 6.3 percentage points lower than 73% in the first quarter of 2011.

China Biologic Products had US$85 million in cash as of Mar. 31, 2012, said the company.






Add this     
Copyright © "2015" www.chinaknowledge.com

Send feedback or comments to: news@chinaknowledge.com

For more news, financial weekly reports, business guides to China, Market Research Reports and other premium information, subscribe to China Knowledge today

To access our page on Bloomberg, type CKFI (GO)

 Our Professional Services

 E-Store

 News Archive
About Us | CSR | Media Center | E-Newsletter | E-Store | Contact Us | Feedback | Sitemap | Privacy Policy | Terms of Use  

           Copyright © 2014 China Knowledge Online. All Rights Reserved